Health Canada has approved a hepatitis B treatment that can deliver a “functional cure” for some people with chronic infection, though specialists caution that its benefits reach a minority of patients and questions remain about cost, access and durability.

CBC News reports that the drug, bepirovirsen, received approval in early November. Manufacturer GSK expects to introduce it in Canada in early 2027.

The treatment is a short-term course of injections. In clinical trials comparing it with a placebo, around one-fifth of patients had undetectable levels of viral DNA in their blood and continued to have the virus under control 24 weeks after stopping all other hepatitis B treatments, according to CBC’s reporting.

That offers a potential alternative to the long-term antiviral therapy patients have required to suppress the virus, Dr. Curtis Cooper, who leads the Ottawa Hospital’s viral hepatitis program, told CBC.

Dr. Carla Coffin, a hepatologist and professor at the University of Calgary, described the treatment as a “major step forward,” but emphasized the need to carefully select patients. People with a history of cirrhosis, or permanent liver scarring, do not qualify, she said. The injections can also cause more side effects, including a rash, than daily antiviral medication.

The duration of the benefit remains uncertain. Coffin said the latest data show an effect lasting at least 96 weeks, but longer follow-up is needed to establish whether it persists.

Affordability is another unresolved issue. Dr. Eric Yoshida, a University of British Columbia medicine professor, told CBC that a course costs roughly $84,000 Cdn in Japan, where the drug was approved earlier. Canadian pricing is not yet clear, nor is whether provincial or private drug plans will cover it.

An estimated 260,000 Canadians live with hepatitis B, roughly half without knowing they are infected, CBC reported. Chronic infection can lead to liver cancer or liver failure. Infection acquired in infancy or childhood is more likely to become chronic, while most healthy adults clear the virus themselves.

Coffin and Yoshida also stressed prevention through vaccination. In November, Canada’s vaccine advisers recommended hepatitis B vaccination for all infants, a change that could eventually bring greater consistency to provincial schedules that currently offer the shot at different ages.

Sources